DNAPrint Cash from 2010 to 2026
DNAPrint Genomics' Cash is increasing over the last several years with slightly volatile swings. Cash is predicted to flatten to about 584.1 K. Cash is the total amount of money in the form of currency that DNAPrint Genomics has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.
Cash | First Reported 2010-12-31 | Previous Quarter 683.9 K | Current Value 584.1 K | Quarterly Volatility 143.2 K |
Check DNAPrint Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DNAPrint Genomics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.8 M or Total Revenue of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.0 or Days Sales Outstanding of 12.22. DNAPrint financial statements analysis is a perfect complement when working with DNAPrint Genomics Valuation or Volatility modules.
DNAPrint | Cash | Build AI portfolio with DNAPrint Stock |
The Cash trend for DNAPrint Genomics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether DNAPrint Genomics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest DNAPrint Genomics' Cash Growth Pattern
Below is the plot of the Cash of DNAPrint Genomics over the last few years. Cash refers to the most liquid asset of DNAPrint Genomics, which is listed under current asset account on DNAPrint Genomics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from DNAPrint Genomics customers. The amounts must be unrestricted with restricted cash listed in a different DNAPrint Genomics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. DNAPrint Genomics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DNAPrint Genomics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
DNAPrint Cash Regression Statistics
| Arithmetic Mean | 565,264 | |
| Geometric Mean | 484,208 | |
| Coefficient Of Variation | 25.34 | |
| Mean Deviation | 64,619 | |
| Median | 594,681 | |
| Standard Deviation | 143,228 | |
| Sample Variance | 20.5B | |
| Range | 667.9K | |
| R-Value | 0.45 | |
| Mean Square Error | 17.5B | |
| R-Squared | 0.20 | |
| Significance | 0.07 | |
| Slope | 12,669 | |
| Total Sum of Squares | 328.2B |
DNAPrint Cash History
Other Fundumenentals of DNAPrint Genomics
| Other Cashflows From Financing Activities | ||
| Total Cash From Operating Activities | ||
| Total Cash From Financing Activities | ||
| Change In Cash |
DNAPrint Genomics Cash component correlations
Click cells to compare fundamentals
About DNAPrint Genomics Financial Statements
DNAPrint Genomics stakeholders use historical fundamental indicators, such as DNAPrint Genomics' Cash, to determine how well the company is positioned to perform in the future. Although DNAPrint Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DNAPrint Genomics' assets and liabilities are reflected in the revenues and expenses on DNAPrint Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DNAPrint Genomics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash | 683.9 K | 584.1 K | |
| Other Cashflows From Financing Activities | -121.5 K | -115.4 K | |
| Total Cash From Operating Activities | -5.2 M | -4.9 M | |
| Total Cash From Financing Activities | 5.1 M | 3.3 M | |
| Change In Cash | -1.1 M | -1 M | |
| Total Cashflows From Investing Activities | 146.9 K | 154.2 K | |
| Other Cashflows From Investing Activities | 637.8 K | 669.7 K | |
| Free Cash Flow Yield | (2.14) | (2.03) | |
| Operating Cash Flow Per Share | (0.01) | (0.01) | |
| Free Cash Flow Per Share | (0.02) | (0.02) | |
| Cash Per Share | 0.02 | 0.01 | |
| Capex To Operating Cash Flow | (0.06) | (0.06) | |
| EV To Operating Cash Flow | (1.56) | (1.64) | |
| EV To Free Cash Flow | (1.46) | (1.53) | |
| Price To Operating Cash Flows Ratio | (0.52) | (0.54) | |
| Price To Free Cash Flows Ratio | (0.48) | (0.51) | |
| Cash Ratio | 0.04 | 0.04 | |
| Cash Conversion Cycle | (560.06) | (588.07) | |
| Operating Cash Flow Sales Ratio | (2.14) | (2.25) | |
| Free Cash Flow Operating Cash Flow Ratio | 1.23 | 1.14 | |
| Cash Flow Coverage Ratios | (0.71) | (0.75) | |
| Price Cash Flow Ratio | (0.52) | (0.54) | |
| Cash Flow To Debt Ratio | (0.71) | (0.75) |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Can Biotechnology industry sustain growth momentum? Does DNAPrint have expansion opportunities? Factors like these will boost the valuation of DNAPrint Genomics. Projected growth potential of DNAPrint fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating DNAPrint Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DNAPrint Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DNAPrint Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DNAPrint Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.